StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$8.53−0.23 (-2.68%)

Close on Nov 13, 2026Market cap $1.41BP/E –Yield –

Novavax gross margin

Gross margin is gross profit as a percentage of revenue.

Novavax's gross margin for the twelve months ending Sep 30, 2026 was 78.0%. For fiscal 2025 it was 93.5%, against 70.3% the year before. The highest annual figure on record is 100.0% in fiscal 2020.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202593.5%+23.2
FY2024Dec 31, 202470.3%+5.2
FY2023Dec 31, 202365.1%+10.6
FY2022Dec 31, 202254.5%−45.5
FY2021Dec 31, 2021100.0%+0.0
FY2020Dec 31, 2020100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 202665.6%−3.9
Q2 FY2026Jun 30, 202674.9%−18.7
Q1 FY2026Mar 31, 202678.0%−19.9
Q4 FY2025Dec 31, 202585.0%+26.5
Q3 FY2025Sep 30, 202569.5%+41.2
Q2 FY2025Jun 30, 202593.6%+4.7
Q1 FY2025Mar 31, 202597.9%+61.0
Q4 FY2024Dec 31, 202458.5%+11.7
Q3 FY2024Sep 30, 202428.3%−18.8
Q2 FY2024Jun 30, 202488.9%+2.0
Q1 FY2024Mar 31, 202436.9%−21.0
Q4 FY2023Dec 31, 202346.8%−2.3
Q3 FY2023Sep 30, 202347.1%+6.3
Q2 FY2023Jun 30, 202386.9%+132.7
Q1 FY2023Mar 31, 202357.9%−39.9
Q4 FY2022Dec 31, 202249.1%−50.9
Q3 FY2022Sep 30, 202240.8%−59.2
Q2 FY2022Jun 30, 2022-45.8%−145.8
Q1 FY2022Mar 31, 202297.8%−2.2
Q4 FY2021Dec 31, 2021100.0%–
Q3 FY2021Sep 30, 2021100.0%–
Q2 FY2021Jun 30, 2021100.0%–
Q1 FY2021Mar 31, 2021100.0%–

More Novavax figures

See a number that looks wrong?